Tokyo, Jan. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058123) titled 'Multicenter Analysis of Adverse Events Associated with Induction Chemotherapy in Metastatic Testicular Tumors: Age-Based Comparison of Patients Aged 50 Years and Older Versus Younger Than 50 Years' on Jan. 1.
Study Type:
Observational
Primary Sponsor:
Institute - International University of Health and Welfare Narita Hospital
Condition:
Condition - metastatic testicular tumors
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The purpose of this study is to retrospectively observe the adverse events of BEP, EP, and VIP therapy as induction chemotherapy for metastatic testicular tumors in elderly patients aged 50 years or older using a retrospective database from multiple institutions, and to clarify their characteristics and frequency in comparison with those aged less than 50 years.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 50
years-old
Gender - Male
Key inclusion criteria - 1)Patients with histologically proven testicular tumors
2)Patients with unresectable tumors or metastases to other organs
3)Patients who have received BEP, EP, or VIP therapy
Key exclusion criteria - 1) Patients with active cancer originating in other organs at the start of BEP, EP, or VIP therapy
2) Patients with incomplete data or who cannot be followed up
Target Size - 183
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 06 Month 09 Day
Anticipated trial start date - 2025 Year 09 Month 01 Day
Last follow-up date - 2025 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066435
Disclaimer: Curated by HT Syndication.
